- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Lakefront Biotherapeutics NV(LKFT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LKFT
11/13/2026: LKFT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Lakefront Biotherapeutics NV is a clinical-stage biopharmaceutical company specializing in immunology and inflammation therapies, operating under its newly reset corporate identity. The company's primary strength lies in its exceptionally robust cash position and its focused pipeline anchored by lead asset gamgertamig. Its core investment story revolves around advancing targeted autoimmune treatments and strategically deploying capital toward high-potential clinical opportunities. Key risks include clinical trial execution uncertainties, regulatory hurdles, and intense competition in the biopharmaceutical sector. The stock suits growth-oriented or momentum investors comfortable with biotechnology risk, requiring close monitoring of upcoming clinical data readouts and pipeline developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential clinical-stage growth catalysts driven by its specialized immunology pipeline, balanced by a transitional business model. |
| Momentum investor | Strong fit while signal remains positive | Technical breakouts and positive clinical trial updates can trigger strong short-term upward momentum. |
| Value investor | Mixed fit | Substantial cash reserves relative to market capitalization provide asset backing, though lack of commercial earnings limits traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing entirely on clinical development and capital allocation. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks carry inherent binary clinical trial and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices frequently fluctuate in response to clinical data releases and market sentiment shifts. |
| Valuation risk | Medium | Valuation relies heavily on pipeline potential and cash backing rather than immediate product sales. |
| Competition risk (immunology biotherapeutics) | High | Numerous large competitors are actively developing alternative treatments for autoimmune and inflammatory diseases. |
| Business quality | Medium | The company benefits from exceptional financial liquidity but is currently transitioning its operating scope. |
| Dividend income | Low / none | No dividend distributions are currently provided to shareholders. |
| Execution risk | High | Success depends on successfully executing clinical trials and advancing pipeline assets through regulatory approvals. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.24B USD | Price to earnings Ratio 2.44 | 1Y Target Price 30.41 |
Price to earnings Ratio 2.44 | 1Y Target Price 30.41 | ||
Volume (30-day avg) 280.3K shares | Beta 0.01 | 52 Weeks Range 25.68 - 36.24 | Updated Date 11/15/2026 |
52 Weeks Range 25.68 - 36.24 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 13.94 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -11.76% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Immunology Therapeutics & Licensing | Future commercialization milestones, product sales, and collaborative licensing revenues derived from clinical-stage assets like gamgertamig. | Revenue generation currently depends on clinical development progress, partnership agreements, and eventual product approvals rather than steady commercial sales. |
Valuation
Trailing PE 2.44 | Forward PE 344.83 | Enterprise Value -211.34M | Price to Sales(TTM) 2.26 |
Enterprise Value -211.34M | Price to Sales(TTM) 2.26 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -31.5 | Shares Outstanding 65.90M | Shares Floating 461.79M |
Shares Outstanding 65.90M | Shares Floating 461.79M | ||
Percent Insiders 26.43 | Percent Institutions 24.14 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

